A Superstable Homogeneous Lipiodol-Nanoformulation to Overcome the Dilemma of Interventional Embolization Chemotherapy

Peng, Yujia; He, Pan; Gao, Xing; Liu, Gang; Cheng, Hongwei

doi:10.3389/fbioe.2022.952194

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently developed SHIFT ICG and SHIFT nanoICG have been applied in clinical trials of advanced HCC in many hospitals, obtaining satisfactory results through fluorescence-guided surgical navigation and embolization therapy. It is worth mentioning that the SHIFT technique could perfectly solve a clinical problem of difficult dispersion of strongly hydrophilic chemotherapeutic drug ( e.g., doxorubicin hydrochloride) in lipiodol for chemoembolization, showing long-lasting stability, sustaining drug release; it exhibits expected embolotherapeutic result for patients with advanced HCC. − SHIFT technique provides a promising tool to solve clinical challenges of diagnostic and therapeutic procedures, offering hope to advanced patients in despair.…”

Section: Discussionmentioning

confidence: 99%

Recent Advances in Interventional Fluorescence Imaging: Toward the Precise Visualization of Transarterial Mini-Invasive Delivery Systems

et al. 2023

Self Cite

View full text Add to dashboard Cite

Interventional fluorescence imaging has gradually developed into a promising imaging strategy for the diagnosis of diseases in clinic. This strategy could benefit interventional targeted treatment because of the clear display of microstructures at the margins and boundaries. There are some stranded crucial issues in clinical application: (i) fast clearance of fluorescence probes; (ii) light instability and photobleaching; and (iii) residual and microsatellite lesions. The development of superstable homogeneous intermixed formulation technology (SHIFT) can solve the aforementioned clinical problems for precision hepatectomy. Interventional fluorescence imaging based on SHIFT-prepared product has some advantages such as (i) strong stability, (ii) greatly extending imageable time window, and (iii) precisely visualizing microsatellite lesions. In this Account, we overview our current progress in interventional fluorescence imaging based on SHIFT method for surgical resection following long-lasting embolization conversion. To greatly realize interventional fluorescence imaging, we summarize clinical and preclinical application of interventional fluorescence imaging in a transarterial delivery system. Indeed, compared with conventional fluorescence imaging, interventional fluorescence imaging possesses non-negligible strengths on improved intensity in target location and step-down systemic toxicity. Unfortunately, a challenging issue is that immobile fluorescence performance is difficult to maintain after long-time embolization, resulting in a failed hepatectomy. On this basis, associated with our previous research, SHIFT was proposed and developed. Thus, we detailedly introduce and account the development and preponderance of SHIFT on interventional fluorescence imaging. Predictably, after lengthy embolization, its lightful fluorescence was still observable in tumor targets of a clinical trial. To regulate the fluorescence rendering of microsatellite lesion, SHIFT combining with pure nanoprobes (nanoICG) occurs, namely SHIFT nanoICG, and we dwell on its performance in transarterial invasive surgical navigation and its clinical application under interventional fluorescence imaging compared with conventional indocyanine green (ICG) formulations. Amazingly, the SHIFT nanoICG brings us an extraordinary imaging consequence for deep-seated tumor tissues and imperceptible microsatellite lesions. Finally, we offer perspectives on the future tendency of interventional imaging-guided SHIFT products in clinical translation such as chemoembolization, radioembolization, and immunotherapy. Actually, these directions have been underway for some time, and even relative products are already applied for clinical trials, exhibiting effective therapeutic outcomes. Our green high-performance SHIFT products are concentrated on meeting clinical needs and solving clinical problems, breaking through the cure limitations of patients with advanced diseases. Thus, the discovery offers insight into the development and superiority of SHIFT product...

show abstract

Section: Discussionmentioning

confidence: 99%

Recent Advances in Interventional Fluorescence Imaging: Toward the Precise Visualization of Transarterial Mini-Invasive Delivery Systems

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Traditional manual and three-way tube mixing methods for preparing iodized oil and drug emulsions are limited by the relatively low drugloading capacity and poor physical stability of the hydrophobic iodized oil and hydrophilic drug formulations. As a result, the drugs are quickly released into circulation, leading to poor therapeutic effects and severe adverse events [7,8]. The alternative method of drug-loaded microsphere embolization is costly and less effective due to microsphere size limitations [9].…”

mentioning

confidence: 99%

Super‐stable homogeneous embolic agents advance the treatment of hepatocellular carcinoma

et al. 2023

Self Cite

View full text Add to dashboard Cite

“…A phase 2 clinical trial has shown that treatment with nab-paclitaxel and gemcitabine-cisplatin (GC) had longer PFS and OS than GC alone (Shroff et al, 2019). The mechanisms underlying the antitumor effects of nab-paclitaxel include the promotion of tumor-associated antigen release, increased infiltration of tumor-infiltrating lymphocytes, and enhanced tumor cell permeability to granzyme (Weiss et al, 2017;Martin et al, 2020;Peng et al, 2022). Based on these encouraging results, combination therapy consisting of sintilimab, lenvatinib, and chemotherapy might be an optimal choice for cHCC-CCA.…”

mentioning

confidence: 99%

Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma

Zhou,

Lei,

Tan

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a highly aggressive malignancy with a poor prognosis. However, there are no consensus treatment guidelines, and decisions are usually extrapolated from intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC). Given that cHCC-CCA owns the unequivocal presence of both hepatocytic and cholangiocytic differentiation, a combination regimen of anti-PD1 antibody, multikinase inhibitor, and chemotherapy targeting against both components might be an optimal choice.Case presentation: We present the case of a patient with postoperative metastatic chemotherapy-resistant cHCC-CCA who exhibited a durable response and reasonable tolerability to a combination therapy consisting of the anti-PD1 antibody sintilimab, multikinase inhibitor lenvatinib, and nab-paclitaxel, despite having a low tumor mutational burden (TMB-L), microsatellite stability (MSS), and negative programmed cell death 1 ligand 1 (PD-L1).Conclusion: The combination regimen of immune checkpoint inhibitor sintilimab, multikinase inhibitor lenvatinib, and chemotherapy with nab-paclitaxel, which targets both the HCC and ICC components, may represent a promising treatment option for patients with cHCC-CCA. Further research is warranted to validate these findings in larger patient cohorts.

show abstract

A Superstable Homogeneous Lipiodol-Nanoformulation to Overcome the Dilemma of Interventional Embolization Chemotherapy

Cited by 4 publications

References 19 publications

Recent Advances in Interventional Fluorescence Imaging: Toward the Precise Visualization of Transarterial Mini-Invasive Delivery Systems

Recent Advances in Interventional Fluorescence Imaging: Toward the Precise Visualization of Transarterial Mini-Invasive Delivery Systems

Super‐stable homogeneous embolic agents advance the treatment of hepatocellular carcinoma

Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma

Contact Info

Product

Resources

About